LEPTIN AS AN INDUCER OF INFLAMMATION AND OXIDATIVE STRESS BY METABOLIC SYNDROME
https://doi.org/10.20538/1682-0363-2014-1-20-26
Abstract
Object of research: to explore the relationship of leptin level in blood serum with markers of systemic inflammation and spontaneous production of cytokines and reactive oxygen species by blood mononuclear leukocytes at metabolic syndrome.
Material and methods. We conducted a study of 50 patients with essential hypertension stage II in conjunction with the metabolic syndrome. Along with a complete clinical, laboratory and instrumental examination adopted in specialized cardiological clinic, were determined the concentration of markers of systemic inflammation and leptin in blood serum, as well as the relative abundance of the surface markers CD4+-, CD8+-lymphocytes and CD36+-monocytes, the level of spontaneous production of proand antiinflammatory cytokines and active oxygen species by blood mononuclear leukocytes.
Results. It was found that patients with essential hypertension stage II with the MS having hyperleptinemia statistically significantly differ both as greater activity of systemic inflammation, and have a greater percentage of CD4+-lymphocytes and a higher level of spontaneous production of blood mononuclear leukocytes a number of proinflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α, MCP-1) and reactive oxygen species.
About the Author
I. D. Bespalovа
Siberian State Medical University, Tomsk
Russian Federation
Bespalovа Inna D.
Russian Federation
Bespalovа Inna D.
References
1. Bespalova I.D., Medyantsev Yu.A., Kalyuzhin V.V., Murashev B.Yu., Osikhov I.A. The quality of life of hypertensive patients with metabolic syndrome. Hypertension, 2012, vol. 18, no. 4, pp. 304–309 (in Russian).
2. Bespalova I.D., Medyantsev Yu.A., Kalyuzhin V.V. Quality of life in patients with coronary heart disease: the relationship with the components of the metabolic syndrome and markers of systemic inflammation. Bulletin of Siberian Medicine, 2012, no. 6, pp. 17–20 (in Russian).
3. Bespalova I.D., Kalyuzhin V.V., Ryazantseva N.V., Medyantsev Yu.A., Murashev B.Yu., Osikhov I.A. The Effect of the 8-week treatment with atorvastatin on Quality of life of hypertensive patients with metabolic syndrome. Hypertension, 2013, vol. 19, no. 2, pp. 125–131 (in Russian).
4. Kalyuzhin V.V., Teplyakov A.T., Ryazantseva N.V., Bespalova I.D., Kamaev D.Yu., Kalyuzhina Ye.V. Quality of life in patients with coronary heart disease associated with the metabolic syndrome: results of the factor analysis. Therapeutic Archive, 2012, no. 12, pp. 18–22 (in Russian).
5. Makolkin V.I. The metabolic syndrome. Moscow, Med. in form. agentstvo Publ., 2010. 144 p (in Russian).
6. Mychka V.B., Zhernakova Yu.V., Chazova I.Ye. Recommendations of the experts of the All-Russian Society of Cardiology on the diagnosis and treatment of the metabolic syndrome (second revision). Moscow, Doctor. Ru, 2010. 18 p. (in Russian).
7. Mottillo S., Filion K.B., Genest J. et al. Metabolic syndrome and cardiovascular risk: a systematic review and metaanalysis. J. Am. Coll. Cardiol., 2010, vol. 56, no. 14. pp. 11131132.
8. Potenza M.V., Mechanick J.I. The metabolic syndrome: definition, global impact, and pathophysiology. Nutr. Clin. Pract., 2009, vol. 24, no. 5. pp. 560–577.
9. Bespalova I.D., Ryazantseva N.V., Kalyuzhin V.V., Afanas'eva D.S., Murashev B.Yu., Osikhov I.A. Systemic inflammation in the pathogenesis of the metabolic syndrome and its associated diseases. The Siberian Medical Journal (Irkutsk), 2013, no. 2, pp. 5–9 (in Russian).
10. Kalyuzhin V.V., Sibireva O.F., Bespalova I.D., Kalyuzhina Ye.V., Tkalich L.M., Milovanova T.A., Osikhov I.A., Murashev B.Yu. Prothrombotic state of patients with metabolic syndrome: association with inflammation. Therapeutic Archive, 2013, no. 10, pp. 29–33 (in Russian).
11. Drapkina O.M., Korneeva O.N., Palatkina L.O. Adipokines and cardiovascular diseases: impact on pathogenesis and therapeutic perspectives. Hypertension, 2011, vol. 17, no. 3, pp. 203–208 (in Russian).
12. Shvarts V. Adipose tissue as an endocrine organ. Problems of Endocrinology. 2009, vol. 55, no. 1, pp. 38–44 (in Russian).
13. Beltowski J. Leptin and atherosclerosis. Atherosclerosis, 2006, vol. 189, no 1, pp. 47–60.
14. ESC Committee for Practice Guidelines to improve the quality of clinical practice and patient care in Europe. 2008. 186 p. (in Russian).
15. Totolyan A.A., Baldueva I.A., Bubnova L.N. Standardization of immunophenotyping of human blood and bone marrow. Clinical Laboratory Diagnostics, 2002, no. 1, pp. 44–50 (in Russian).
16. Minyaylova N.N., Sundukova E.L., Rovda Yu.I. Hyperleptinemia and its clinical association with metabolic syndrome, insulin resistance in children and adolescents. Pediatrics, 2009, vol. 88, no. 6, pp. 6–13 (in Russian).
17. Chaitov R.M. Immunology: textbook for medical students. Moscow, GEOTAR-Media Publ., 2006. C. 320 (in Russian).
18. Chasovskikh N.Yu., Ryazantseva N.V., Kaygorodova Ye.V., Chechina O.Ye., Sokolovich Ye.G., Novitskiy V.V. Condition system of MAP kinases JNK and p38 in mononuclear blood leukocytes in inflammation. Medical Immunology, 2009, vol. 11, no. 6, pp. 515–522 (in Russian).
19. Klebanova Ye.M., Balabolkina M.I. Hormones of adipose tissue and its role in the pathogenesis of type 2 diabetes. The Attending Physician, 2010, no. 11, pp. 12–16 (in Russian).
Review
For citations:
Bespalovа I.D. LEPTIN AS AN INDUCER OF INFLAMMATION AND OXIDATIVE STRESS BY METABOLIC SYNDROME. Bulletin of Siberian Medicine. 2014;13(1):20-26. (In Russ.) https://doi.org/10.20538/1682-0363-2014-1-20-26
Views:
1153
Email this article 